Select Page

GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.
Conference details are as follows:Citi 15th Annual BioPharma Virtual ConferenceH.C. Wainwright 22nd Annual Global Investment ConferenceCantor Virtual Global Healthcare ConferenceMorgan Stanley Virtual 18th Annual Global Healthcare ConferenceLeerink CyberRx Series: Vaccine ForumA replay of the presentations will also be accessible under the “Investors/Events” section NovavaxNovavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.For more information, visit and connect with us on Twitter and LinkedIn.
Silvia Taylor and Erika Trahan
Brandzone/KOGS Communication
Edna Kaplan